New and investigational treatments in cystic fibrosis
Author(s) -
Mangala Narasimhan,
Rubin I. Cohen
Publication year - 2011
Publication title -
therapeutic advances in respiratory disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.022
H-Index - 37
eISSN - 1753-4666
pISSN - 1753-4658
DOI - 10.1177/1753465811398267
Subject(s) - cystic fibrosis , medicine , antibiotics , intensive care medicine , intravenous antibiotics , investigational drugs , quality of life (healthcare) , clinical trial , genetics , nursing , biology
Cystic fibrosis (CF) is an autosomal recessive disorder that affects approximately 1 in 3000 Caucasian births, or 30,000 individuals in the US and 70,000 worldwide. The discovery of the CF gene, isolation of the CFTR protein and understanding of molecular mechanisms behind the clinical expression of CF are being translated into newer treatments. Treatments for CF and its manifestations are discussed in this article including inhaled antibiotics, hydrator therapies, anti-inflammatory agents and protein modifiers. New and experimental treatments that are in development are also discussed. Outcomes for these treatments are forced expiratory volume in one second (FEV 1 ) improvement, CF-related quality of life, use of intravenous antibiotics and frequency of exacerbations and hospitalizations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom